Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8415)
All Articles published online
|
Feb 10, 2011 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93 [PMID: 21603317 DOI: 10.5306/wjco.v2.i2.80] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm |
| Number | Citing Articles |
| 1 |
Aishwarya Shinde, Kanan Panchal, Sumeet Katke, Rishi Paliwal, Akash Chaurasiya. Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives. Therapies 2022; 77(4): 425 doi: 10.1016/j.therap.2021.10.010
|
| 2 |
Aleksandra Sochacka-Ćwikła, Marcin Mączyński, Andrzej Regiec. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022; 27(7): 2259 doi: 10.3390/molecules27072259
|
| 3 |
Maria Kalyukina, Yuliana Yosaatmadja, Martin J. Middleditch, Adam V. Patterson, Jeff B. Smaill, Christopher J. Squire. TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem 2019; 14(4): 494 doi: 10.1002/cmdc.201800719
|
| 4 |
Models of Nanostructures Based on Titanium Dioxide TiO for Transport of Biologically Active Compounds. Nanosistemi, Nanomateriali, Nanotehnologii 2020; 18(4) doi: 10.15407/nnn.18.04.1077
|
| 5 |
Areej Abuhammad, Mutasem Taha. Innovative computer-aided methods for the discovery of new kinase ligands. Future Medicinal Chemistry 2016; 8(5): 509 doi: 10.4155/fmc-2015-0003
|
| 6 |
Sanja Aveic, Gian Paolo Tonini. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?. Cancer Cell International 2016; 16(1) doi: 10.1186/s12935-016-0341-2
|
| 7 |
Cristina Olgasi, Patrizia Dentelli, Arturo Rosso, Alessandra Iavello, Gabriele Togliatto, Valentina Toto, Marcella Liberatore, Giuseppina Barutello, Piero Musiani, Federica Cavallo, Maria Felice Brizzi. DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis. European Journal of Cancer 2014; 50(1): 234 doi: 10.1016/j.ejca.2013.09.016
|
| 8 |
Eman A. Abd El-Meguid, Ahmed M. Naglah, Gaber O. Moustafa, Hanem M. Awad, Ahmed M. El Kerdawy. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Bioorganic & Medicinal Chemistry Letters 2022; 58: 128529 doi: 10.1016/j.bmcl.2022.128529
|
| 9 |
Darawan Rinchai, Elena Verzoni, Veronica Huber, Agata Cova, Paola Squarcina, Loris De Cecco, Filippo de Braud, Raffaele Ratta, Matteo Dugo, Luca Lalli, Viviana Vallacchi, Monica Rodolfo, Jessica Roelands, Chiara Castelli, Damien Chaussabel, Giuseppe Procopio, Davide Bedognetti, Licia Rivoltini. Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine 2021; 11(6) doi: 10.1002/ctm2.434
|
| 10 |
Xiaoxiao Sun, Qiaoling Song, Li He, Lei Yan, Jingli Liu, Qing Zhang, Qiang Yu. Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment. Molecular Cancer Therapeutics 2016; 15(10): 2508 doi: 10.1158/1535-7163.MCT-15-0735
|
| 11 |
Simone De Leo, Matteo Trevisan, Claudia Moneta, Carla Colombo. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Annales d'Endocrinologie 2023; 84(3): 374 doi: 10.1016/j.ando.2023.03.009
|
| 12 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 695 doi: 10.1016/B978-0-12-809400-6.00029-9
|
| 13 |
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman, Rakesh Naidu. Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.772510
|
| 14 |
Jijin Wang, Di Huang, Wenjing Yang, Qingxu Song, Yibin Jia, Pengxiang Chen, Yufeng Cheng. The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1030798
|
| 15 |
Bashdar Mahmud Hussen, Khozga Hazhar Abdullah, Snur Rasool Abdullah, Nasik Mahmood Majeed, Sayran Mohamadtahr, Mohammed Fatih Rasul, Peixin Dong, Mohammad Taheri, Majid Samsami. New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets. Non-coding RNA Research 2023; 8(4): 645 doi: 10.1016/j.ncrna.2023.09.003
|
| 16 |
Priyanka Gupta, Keehn Strange, Rahul Telange, Ailan Guo, Heather Hatch, Amin Sobh, Jonathan Elie, Angela M. Carter, John Totenhagen, Chunfeng Tan, Yogesh A. Sonawane, Jiri Neuzil, Amarnath Natarajan, Ashley J. Ovens, Jonathan S. Oakhill, Thorsten Wiederhold, Karel Pacak, Hans K. Ghayee, Laurent Meijer, Sushanth Reddy, James Bibb. Genetic Impairment of Succinate Metabolism Disrupts Bioenergetic Sensing in Adrenal Neuroendocrine Cancer. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4018612
|
| 17 |
Venice Wing Tung Ho, Hor Yue Tan, Ning Wang, Yibin Feng. Tyrosine Kinases as Druggable Targets in Cancer. 2019; doi: 10.5772/intechopen.82513
|
| 18 |
Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée, Nor Eddine Sounni. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers 2020; 12(3): 731 doi: 10.3390/cancers12030731
|
| 19 |
Maša Kenda, Damjan Avsec, Taja Zore, Eva Kogovšek, Urša Pečar Fonović, Janko Kos, Krištof Bozovičar, Tomaž Bratkovič, Nataša Karas Kuželički, Bojana Žegura, Metka Filipič, Marija Sollner Dolenc. Effects of tyrosine kinase inhibitors on androgen, estrogen α, glucocorticoid and thyroid receptors. Toxicology and Applied Pharmacology 2022; 434: 115818 doi: 10.1016/j.taap.2021.115818
|
| 20 |
Siva M Gangadhar, Mithilesh Yadav, Nishith S Mandal. Dermatofibrosarcoma Protuberans: A Surgeon's Enigma. Cureus 2023; doi: 10.7759/cureus.44144
|
| 21 |
Mustafa A. Al-Qadhi, Heba Abdelrasheed Allam, Samar H. Fahim, Tawfeek A.A. Yahya, Fatma A.F. Ragab. Design and synthesis of certain 7-Aryl-2-Methyl-3-Substituted Pyrazolo{1,5-a}Pyrimidines as multikinase inhibitors. European Journal of Medicinal Chemistry 2023; 262: 115918 doi: 10.1016/j.ejmech.2023.115918
|
| 22 |
Jian Wu, Suresh Kumar, Feng Wang, Hui Wang, Lijia Chen, Patrick Arsenault, Michael Mattern, Joseph Weinstock. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. Journal of Medicinal Chemistry 2018; 61(2): 422 doi: 10.1021/acs.jmedchem.7b00498
|
| 23 |
Francesco Sabbatino, Valeria Conti, Luigi Liguori, Giovanna Polcaro, Graziamaria Corbi, Valentina Manzo, Vincenzo Tortora, Chiara Carlomagno, Carmine Vecchione, Amelia Filippelli, Stefano Pepe. Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. Life 2021; 11(2): 105 doi: 10.3390/life11020105
|
| 24 |
Aiten M. Soliman, Mostafa M. Ghorab. Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. Bioorganic Chemistry 2019; 88: 102956 doi: 10.1016/j.bioorg.2019.102956
|
| 25 |
Anh Thu Vu, Lara Akingunsade, Konstantin Hoffer, Cordula Petersen, Christian Stephan Betz, Kai Rothkamm, Thorsten Rieckmann, Lara Bussmann, Malte Kriegs. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib. Head & Neck 2023; 45(1): 147 doi: 10.1002/hed.27216
|
| 26 |
Eman M.E. Dokla, Amal Kamal Abdel-Aziz, Sandra N. Milik, Amr H. Mahmoud, Mona Kamal Saadeldin, Martin J. McPhillie, Saverio Minucci, Khaled A.M. Abouzid. Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry 2021; 117: 105451 doi: 10.1016/j.bioorg.2021.105451
|
| 27 |
Robert I. Haddad, Martin Schlumberger, Lori J. Wirth, Eric J. Sherman, Manisha H. Shah, Bruce Robinson, Corina E. Dutcus, Angela Teng, Andrew G. Gianoukakis, Steven I. Sherman. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017; 56(1): 121 doi: 10.1007/s12020-017-1233-5
|
| 28 |
Shelly Pathania, Olli T. Pentikäinen, Pankaj Kumar Singh. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021; 1876(2): 188631 doi: 10.1016/j.bbcan.2021.188631
|
| 29 |
Bibian M. E. Tullemans, Magdolna Nagy, Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G. A. oude Egbrink, Maureen Aarts, Johan W. M. Heemskerk, Marijke J. E. Kuijpers. Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients. Frontiers in Cardiovascular Medicine 2018; 5 doi: 10.3389/fcvm.2018.00142
|
| 30 |
Sanjay K. Srikakulam, Tomas Bastys, Olga V. Kalinina. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance. Proteins: Structure, Function, and Bioinformatics 2020; 88(11): 1434 doi: 10.1002/prot.25963
|
| 31 |
Samy Mohamady, Mahmoud Galal, Wagdy M. Eldehna, David C. Gutierrez, Hany S. Ibrahim, Mohey M. Elmazar, Hamed I. Ali. Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. ACS Omega 2020; 5(30): 18872 doi: 10.1021/acsomega.0c02038
|
| 32 |
Adriana Zámečníkova. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Expert Opinion on Drug Discovery 2014; 9(1): 77 doi: 10.1517/17460441.2014.865012
|
| 33 |
E. A. Shatokhina, L. S. Kruglova, A. S. Polonskaia. Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment. Meditsinskiy sovet = Medical Council 2020; (20): 157 doi: 10.21518/2079-701X-2020-20-157-164
|
| 34 |
Nurmaya Effendi, Kenji Mishiro, Takeshi Takarada, Akira Makino, Daisuke Yamada, Yoji Kitamura, Kazuhiro Shiba, Yasushi Kiyono, Akira Odani, Kazuma Ogawa. Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-28529-0
|
| 35 |
Wen-Hsing Lin, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, Jen-Shin Song, Hui-Yi Shiao, Ching-Chuan Kuo, Tsu Hsu, Cheng-Tai Lu, Pei-Chen Wang, Tsung-Sheng Wu, Yi-Hui Peng, Hui-You Lin, Ching-Ping Chen, Ya-Ling Weng, Fang-Chun Kung, Mine-Hsine Wu, Yu-Chieh Su, Kuo-Wei Huang, Ling-Hui Chou, Ching-Cheng Hsueh, Kuei-Jung Yen, Po-Chu Kuo, Chen-Lung Huang, Li-Tzong Chen, Chuan Shih, Hui-Jen Tsai, Weir-Torn Jiaang. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. Journal of Medicinal Chemistry 2019; 62(24): 11135 doi: 10.1021/acs.jmedchem.9b01229
|
| 36 |
Wagdy M. Eldehna, Ahmed M. El Kerdawy, Ghada H. Al-Ansary, Sara T. Al-Rashood, Mamdouh M. Ali, Abeer E. Mahmoud. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. European Journal of Medicinal Chemistry 2019; 163: 37 doi: 10.1016/j.ejmech.2018.11.061
|
| 37 |
Kyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij, Pongsatorn Tangtawee, Wikran Suragul, Watoo Vassanasiri Farquharson, Kanokpan Wongprasert, Somchai Chutipongtanate, Pimtip Sanvarinda, Marisa Ponpuak, Naravat Poungvarin, Tavan Janvilisri, Tuangporn Suthiphongchai, Kiren Yacqub-Usman, Anna M. Grabowska, David O. Bates, Rutaiwan Tohtong. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals 2024; 17(2): 197 doi: 10.3390/ph17020197
|
| 38 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 145 doi: 10.1016/B978-0-12-809400-6.00007-X
|
| 39 |
Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer. Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research 2013; 19(9): 2541 doi: 10.1158/1078-0432.CCR-13-0107
|
| 40 |
Wenjing Xu, Chunping Ye, Xin Qing, Shengli Liu, Xinyi Lv, Wenjun Wang, Xiaochen Dong, Yewei Zhang. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Materials Today Bio 2022; 16: 100358 doi: 10.1016/j.mtbio.2022.100358
|
| 41 |
Valentina Gandin, Alessandro Ferrarese, Martina Dalla Via, Cristina Marzano, Adriana Chilin, Giovanni Marzaro. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Scientific Reports 2015; 5(1) doi: 10.1038/srep16750
|
| 42 |
Fares Hezam Al-Ostoot, Ankith Sherapura, Vikas H. Malojirao, Prabhu Thirusangu, Tahani I. Al-Muhimeed, Shaukath Ara Khanum, B. T. Prabhakar. Modulation of DNA damage response by targeting ATM kinase using newly synthesized di-phenoxy acetamide (DPA) analogs to induce anti-neoplasia. Pharmacological Reports 2021; 73(5): 1344 doi: 10.1007/s43440-021-00292-6
|
| 43 |
Gabor Valcz, Ferenc Sipos, Zsolt Tulassay, Bela Molnar, Yukako Yagi. Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. Postgraduate Medical Journal 2015; 91(1075): 291 doi: 10.1136/postgradmedj-2014-202561rep
|
| 44 |
Rania Kheder El-Fekih, Clément Deltombe, Hassan Izzedine. Microangiopathie thrombotique et cancer. Néphrologie & Thérapeutique 2017; 13(6): 439 doi: 10.1016/j.nephro.2017.01.023
|
| 45 |
Sheetal Chauhan, Seema Sen, Khushboo Irshad, Seema Kashyap, Neelam Pushker, Rachna Meel, Mehar Chand Sharma. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target. Human Cell 2023; 37(1): 297 doi: 10.1007/s13577-023-00993-5
|
| 46 |
Sindhu M. Parameshwaraiah, Rashmi Shivakumar, Zhang Xi, Tejaswini P. Siddappa, Akshay Ravish, Arunkumar Mohan, Lisha K. Poonacha, Pradeep M. Uppar, Shreeja Basappa, Dukanya Dukanya, Santhosh L. Gaonkar, Kempaiah Kemparaju, Peter E. Lobie, Vijay Pandey, Basappa Basappa. Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells. Chemistry & Biodiversity 2024; 21(3) doi: 10.1002/cbdv.202301950
|
| 47 |
Megan L. Troxell, John P. Higgins, Neeraja Kambham. Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Advances in Anatomic Pathology 2016; 23(5): 310 doi: 10.1097/PAP.0000000000000122
|
| 48 |
Zachary S. Peacock, Deepak Kademani, Anh D. Le, Janice S. Lee, Robert G. Hale, Larry L. Cunningham. Proceedings From the 2011 American Association of Oral and Maxillofacial Surgeons Research Summit. Journal of Oral and Maxillofacial Surgery 2012; 70(6): 1271 doi: 10.1016/j.joms.2012.01.029
|
| 49 |
Josep Esteve Romero, Jaume Albiol Chiva, Juan Peris-Vicente, Enrique Ochoa-Aranda. Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma. Bioanalysis 2017; 9(10): 799 doi: 10.4155/bio-2017-0028
|
| 50 |
Aliaksandr Faryna, Elena Kalinichenko. Molecular Docking - Recent Advances. Biomedical Engineering 2023; 15 doi: 10.5772/intechopen.107236
|
| 51 |
Amirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, Bostjan Seruga, Monika K. Krzyzanowska, Eitan Amir, Jung Weon Lee. Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. PLOS ONE 2015; 10(3): e0122735 doi: 10.1371/journal.pone.0122735
|
| 52 |
Jianbiao Zhou, Wee-Joo Chng. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World Journal of Clinical Oncology 2018; 9(5): 90-97 doi: 10.5306/wjco.v9.i5.90
|
| 53 |
Gabor Valcz, Ferenc Sipos, Zsolt Tulassay, Bela Molnar, Yukako Yagi. Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. Journal of Clinical Pathology 2014; 67(12): 1026 doi: 10.1136/jclinpath-2014-202561
|
| 54 |
Haoyue Guo, Binglei Li, Li Diao, Hao Wang, Peixin Chen, Minlin Jiang, Lishu Zhao, Yayi He, Caicun Zhou. An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). OncoImmunology 2021; 10(1) doi: 10.1080/2162402X.2021.1947665
|
| 55 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 57 doi: 10.1016/B978-0-12-809400-6.00003-2
|
| 56 |
Anna M. Ogloblina, Alexandra N. Khristich, Natalia Y. Karpechenko, Svetlana E. Semina, Gennady A. Belitsky, Nina G. Dolinnaya, Marianna G. Yakubovskaya. Multi-targeted effects of G4-aptamers and their antiproliferative activity against cancer cells. Biochimie 2018; 145: 163 doi: 10.1016/j.biochi.2017.11.020
|
| 57 |
Aik-Choon Tan, Simon Vyse, Paul H. Huang. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discovery Today 2017; 22(1): 72 doi: 10.1016/j.drudis.2016.07.010
|
| 58 |
Katie Bechman, James B Galloway, Kevin L Winthrop. Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Current Fungal Infection Reports 2019; 13(4): 229 doi: 10.1007/s12281-019-00350-w
|
| 59 |
Elizabeth Irvine, Casey Williams. Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2013; 33(8): 868 doi: 10.1002/phar.1266
|
| 60 |
Mike-Andrew Westhoff, Nicolas Marschall, Klaus-Michael Debatin. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. Advances in Experimental Medicine and Biology 2016; 930: 173 doi: 10.1007/978-3-319-39406-0_8
|
| 61 |
Kadri Valter, Boris Zhivotovsky, Vladimir Gogvadze. Cell death-based treatment of neuroblastoma. Cell Death & Disease 2018; 9(2) doi: 10.1038/s41419-017-0060-1
|
| 62 |
Nadia Panera, Annalisa Crudele, Ilaria Romito, Daniela Gnani, Anna Alisi. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2017; 18(1): 99 doi: 10.3390/ijms18010099
|
| 63 |
Mohamed Mokhtar, Khadijah S. Alghamdi, Nesreen S. Ahmed, Dina Bakhotmah, Tamer S. Saleh. Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases. Journal of Enzyme Inhibition and Medicinal Chemistry 2021; 36(1): 1453 doi: 10.1080/14756366.2021.1944126
|
| 64 |
Maninder Kaur, Pankaj Kumar Singh, Manjinder Singh, Renu Bahadur, Om Silakari. Molecular dynamics and integrated pharmacophore-based identification of dual $$\hbox {JAK3/PI3K}\delta $$ JAK3/PI3K δ inhibitors. Molecular Diversity 2018; 22(1): 95 doi: 10.1007/s11030-017-9794-z
|
| 65 |
Halyna M. Kuznietsova, Vasyl V. Hurmach, Andriy V. Bychko, Olena I. Tykhoniuk, Demyd S. Milokhov, Olga V. Khilya, Yulian M. Volovenko, Volodymyr K. Rybalchenko. Synthesis and biological activity of 4-amino-3-chloro-1H-pyrrole-2,5-diones. In Silico Pharmacology 2019; 7(1) doi: 10.1007/s40203-019-0051-2
|
| 66 |
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01460-1
|
| 67 |
Heba Abdelrasheed Allam, Enayat E. Aly, Ahmed K.B.A.W. Farouk, Ahmed M. El Kerdawy, Essam Rashwan, Safinaz E.S. Abbass. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Bioorganic Chemistry 2020; 98: 103726 doi: 10.1016/j.bioorg.2020.103726
|
| 68 |
Vikas Pradhan, Salahuddin , Rajnish Kumar, Avijit Mazumder, Mohammad Mustaqeem Abdullah, Mohammad Shahar Yar, Mohamed Jawed Ahsan, Zabih Ullah. Molecular target interactions of quinoline derivatives as anticancer agents: A review. Chemical Biology & Drug Design 2023; 101(4): 977 doi: 10.1111/cbdd.14196
|
| 69 |
Michaela Kuhlen, Jan-Henning Klusmann, Jessica I. Hoell. Molecular Approaches to Treating Pediatric Leukemias. Frontiers in Pediatrics 2019; 7 doi: 10.3389/fped.2019.00368
|
| 70 |
Pascal Dao, Rafika Jarray, Nikaia Smith, Yves Lepelletier, Johanne Le Coq, Daniel Lietha, Réda Hadj-Slimane, Jean-Philippe Herbeuval, Christiane Garbay, Françoise Raynaud, Huixiong Chen. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Cancer Letters 2014; 348(1-2): 88 doi: 10.1016/j.canlet.2014.03.007
|
| 71 |
Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, Halil Mete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 2024; 24(4): 232 doi: 10.1016/j.clml.2023.12.004
|
| 72 |
Liling Huang, Shiyu Jiang, Yuankai Shi. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). Journal of Hematology & Oncology 2020; 13(1) doi: 10.1186/s13045-020-00977-0
|
| 73 |
Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Hardikkumar Jetani, Jesus Gil-Pulido, Matteo Claudio Da Via, Eva Teufel, Nadine Rhodes, Larissa Haertle, Estibaliz Arellano-Viera, Raoul Tibes, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Jürgen Groll, Hermann Einsele, Sabrina Kraus, Martin K. Kortüm. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Communications Biology 2021; 4(1) doi: 10.1038/s42003-021-02215-w
|
| 74 |
Miaomiao Tang, Zhanxuan E. Wu, Fei Li. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors. Computers in Biology and Medicine 2024; 170: 108040 doi: 10.1016/j.compbiomed.2024.108040
|
| 75 |
Thomas D. McLean, Serena Duchi, Claudia Di Bella. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review. Targeted Oncology 2022; 17(3): 223 doi: 10.1007/s11523-022-00876-z
|
| 76 |
M J Cross, B R Berridge, P J M Clements, L Cove‐Smith, T L Force, P Hoffmann, M Holbrook, A R Lyon, H R Mellor, A A Norris, M Pirmohamed, J D Tugwood, J E Sidaway, B K Park. Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury. British Journal of Pharmacology 2015; 172(4): 957 doi: 10.1111/bph.12979
|
| 77 |
Vikash Pandey, Marc Sultan, Karl Kashofer, Meryem Ralser, Vyacheslav Amstislavskiy, Julia Starmann, Ingrid Osprian, Christina Grimm, Hendrik Hache, Marie-Laure Yaspo, Holger Sültmann, Michael Trauner, Helmut Denk, Kurt Zatloukal, Hans Lehrach, Christoph Wierling, Manlio Vinciguerra. Comparative Analysis and Modeling of the Severity of Steatohepatitis in DDC-Treated Mouse Strains. PLoS ONE 2014; 9(10): e111006 doi: 10.1371/journal.pone.0111006
|
| 78 |
George Iancu, Dragos Serban, Cristinel Badiu, Ciprian Tanasescu, Mihai Tudosie, Corneliu Tudor, Daniel Costea, Anca Zgura, Raluca Iancu, Danut Vasile. Tyrosine kinase inhibitors in breast cancer (Review). Experimental and Therapeutic Medicine 2021; 23(2) doi: 10.3892/etm.2021.11037
|
| 79 |
Aisha Al Anaz, Ravi Teja Chitturi Suryaprakash, Kate Shearston, Omar Kujan. Molecular Targets and Cancer Therapeutics (Part 1). 2023; : 187 doi: 10.2174/9789815080384123010008
|
| 80 |
K. G. Kulikov, T. V. Koshlan, A. P. Golovitsky. A Paradigm Shift in Experimental Biochemistry: A Priori Estimation of Physical Parameters of Biomolecules. Biophysical Reviews and Letters 2023; 18(01): 23 doi: 10.1142/S1793048023500017
|
| 81 |
Jung Hoon Lee, Yanxialei Jiang, Yong Tae Kwon, Min Jae Lee. Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications. Trends in Pharmacological Sciences 2015; 36(11): 782 doi: 10.1016/j.tips.2015.07.004
|
| 82 |
Daniel de Klerk, Richard Honeywell, Gerrit Jansen, Godefridus Peters. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers 2018; 10(12): 503 doi: 10.3390/cancers10120503
|
| 83 |
Yanmin Zhang, Yadong Chen, Danfeng Zhang, Lu Wang, Tao Lu, Yu Jiao. Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Journal of Medicinal Chemistry 2018; 61(1): 140 doi: 10.1021/acs.jmedchem.7b01091
|
| 84 |
Hassan Izzedine. Toxicités rénales des thérapies ciblées en oncologie. Néphrologie & Thérapeutique 2020; 16(1): 1 doi: 10.1016/j.nephro.2019.06.003
|
| 85 |
Dong-Myung Kim, Hanna Kim, Ji-Hyun Yeon, Ju-Hee Lee, Han-Oh Park. Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening onS. pombeDeletion Library. Toxicological Sciences 2016; 149(1): 4 doi: 10.1093/toxsci/kfv210
|
| 86 |
Carmen Dominguez-Brauer, Kelsie L. Thu, Jacqueline M. Mason, Heiko Blaser, Mark R. Bray, Tak W. Mak. Targeting Mitosis in Cancer: Emerging Strategies. Molecular Cell 2015; 60(4): 524 doi: 10.1016/j.molcel.2015.11.006
|
| 87 |
Anu R. Melge, K. Manzoor, Shantikumar V. Nair, C. Gopi Mohan. In Silico Drug Design. 2019; : 577 doi: 10.1016/B978-0-12-816125-8.00019-5
|
| 88 |
Shih-Chung Yen, Yi-Wen Wu, Cheng-Chiao Huang, Min-Wu Chao, Huang-Ju Tu, Liang-Chieh Chen, Tony Eight Lin, Tzu-Ying Sung, Hui-Ju Tseng, Jung-Chun Chu, Wei-Jan Huang, Chia-Ron Yang, Wei-Chun HuangFu, Shiow-Lin Pan, Kai-Cheng Hsu. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. Phytomedicine 2022; 100: 154061 doi: 10.1016/j.phymed.2022.154061
|
| 89 |
Praopim Limsakul, Pongsakorn Choochuen, Thawirasm Jungrungrueang, Krit Charupanit. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer. International Journal of Molecular Sciences 2024; 25(3): 1405 doi: 10.3390/ijms25031405
|
| 90 |
Kenar D. Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, Daniel W. Ross, Steven Fishbane. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney International Reports 2017; 2(1): 108 doi: 10.1016/j.ekir.2016.09.055
|
| 91 |
Meenu Chopra, Agustin Sgro, Marck Norret, Pilar Blancafort, K. Swaminathan Iyer, Cameron W. Evans. A peptide-functionalised dendronised polymer for selective transfection in human liver cancer cells. New Journal of Chemistry 2021; 45(41): 19315 doi: 10.1039/D1NJ01566D
|
| 92 |
Vinayak Venkataraman, John R Bales, Jessie Signorelli, Gabriela S Hobbs. Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors. Journal of Oncology Pharmacy Practice 2023; 29(5): 1119 doi: 10.1177/10781552221098044
|
| 93 |
Prakamya Gupta, Ashutosh Rai, Kanchan Kumar Mukherjee, Naresh Sachdeva, Bishan Das Radotra, Raj Pal Singh Punia, Rakesh Kumar Vashista, Debasish Hota, Anand Srinivasan, Sivashanmugam Dhandapani, Sunil Kumar Gupta, Anil Bhansali, Pinaki Dutta. Imatinib Inhibits GH Secretion From Somatotropinomas. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00453
|
| 94 |
Richard J. Honeywell, Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F. Smit, Maria N. Rovithi, Henk M.W. Verheul, Godefridus J. Peters. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers 2020; 12(11): 3322 doi: 10.3390/cancers12113322
|
| 95 |
Vivian Osei Poku, Surtaj Hussain Iram. A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells. PeerJ 2022; 10: e12594 doi: 10.7717/peerj.12594
|
| 96 |
Wei Zhao, Xiao‐Di Zheng, Paula Yun‐Zhi Tang, Hong‐Mei Li, Xue Liu, Jian‐Jiang Zhong, Ya‐Jie Tang. Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi‐active components combination. Medicinal Research Reviews 2023; 43(5): 1778 doi: 10.1002/med.21963
|
| 97 |
Raja Nur Firzanah Syaza Raja Sharin, Jesmine Khan, Mohamad Johari Ibahim, Mudiana Muhamad, Joanne Bowen, Wan Nor I’zzah Wan Mohamad Zain, Supat Chupradit. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review. BioMed Research International 2022; 2022: 1 doi: 10.1155/2022/4165808
|
| 98 |
Aarthi Jayanthan, Yibing Ruan, Tony H. Truong, Aru Narendran, Claude Prigent. Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents. PLoS ONE 2014; 9(7): e102741 doi: 10.1371/journal.pone.0102741
|
| 99 |
Bryan Oronsky, Corey Carter, Anna Scicinska, Arnold Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski. Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. Oncotarget 2016; 7(8): 9041 doi: 10.18632/oncotarget.6984
|
| 100 |
Agnieszka Kotlarz, Małgorzata Przybyszewska, Paweł Swoboda, Jacek Neska, Joanna Miłoszewska, Monika Anna Grygorowicz, Andrzej Kutner, Sergiusz Markowicz. Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells. The Journal of Steroid Biochemistry and Molecular Biology 2019; 189: 48 doi: 10.1016/j.jsbmb.2019.02.003
|
| 101 |
Ying Xiong, Qinxuan Wang, Yangyi Liu, Jingwen Wei, Xiaolei Chen. Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1023660
|
| 102 |
Shruthi Harish Bindiganavile, Nita Bhat, Andrew G. Lee, Dan S. Gombos, Nagham Al-Zubidi. Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. Journal of Immunotherapy and Precision Oncology 2021; 4(1): 6 doi: 10.36401/JIPO-20-21
|
| 103 |
Mojeed Ayoola Ashiru, Sherif Olabisi Ogunyemi, Oluwakemi Rita Temionu, Abosede Christina Ajibare, Nsikak Cicerella Cicero-Mfon, Ogechi Augustina Ihekuna, Monsurat Olatoun Jagun, Latifatu Abdulmumin, Quadri Kolawole Adisa, Yemisi Elizabeth Asibor, Chika Joseph Okorie, Mariam Omowumi Lawal, Musa Oladayo Babalola, Ibrahim Tope Abdulrasaq, Latifat Bukola Salau, Idayat Omotolani Olatunji, Memunat Alake Bankole, Abibat Bisola Daud, Ayodeji Oluwadamilare Adeyemi. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations. Journal of Molecular Modeling 2023; 29(5) doi: 10.1007/s00894-023-05531-6
|
| 104 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 199 doi: 10.1016/B978-0-12-809400-6.00009-3
|
| 105 |
VIDHI DESAI, JYOTSANA THAKKAR, RIMDA WANCHOO, KENAR D. JHAVERI. Onco-Nephrology. 2020; : 154 doi: 10.1016/B978-0-323-54945-5.00026-6
|
| 106 |
Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01469-6
|
| 107 |
Huda K. Mahmoud, Thoraya A. Farghaly, Hanan G. Abdulwahab, Nadia T. Al-Qurashi, Mohamed R. Shaaban. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. European Journal of Medicinal Chemistry 2020; 208: 112752 doi: 10.1016/j.ejmech.2020.112752
|
| 108 |
Frangky Sangande, Elin Julianti, Daryono Hadi Tjahjono. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. International Journal of Molecular Sciences 2020; 21(20): 7779 doi: 10.3390/ijms21207779
|
| 109 |
G. Ganga Reddy, S. Ramakrishna Reddy, Ch. Venkata Ramana Reddy, E. Laxminarayana, B. Srinivasa Reddy. Synthesis, Characterization and Molecular Docking Studies of
5-Chloro-1-(1H-indole-2-yl)-3-methyl-4,5-dihydro-1H-pyrazole-4-carboxylic Acids. Asian Journal of Chemistry 2022; 34(7): 1639 doi: 10.14233/ajchem.2022.23610
|
| 110 |
Halyna Kuznietsova, Natalia Dziubenko, Iryna Byelinska, Vasyl Hurmach, Andriy Bychko, Oksana Lynchak, Demyd Milokhov, Olga Khilya, Volodymyr Rybalchenko. Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety. Journal of Drug Targeting 2020; 28(5): 547 doi: 10.1080/1061186X.2019.1703189
|
| 111 |
Marília I. Figueira, Henrique J. Cardoso, Sara Correia, Cláudio J. Maia, Sílvia Socorro. The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?. Cancer Letters 2017; 405: 10 doi: 10.1016/j.canlet.2017.07.017
|
| 112 |
Sebastian Kallus, Bernhard Englinger, Julia Senkiv, Anna Laemmerer, Petra Heffeter, Walter Berger, Christian R. Kowol, Bernhard K. Keppler. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine: Nanotechnology, Biology and Medicine 2018; 14(8): 2632 doi: 10.1016/j.nano.2018.08.001
|
| 113 |
|
| 114 |
Attila Varga, Pál Gyulavári, Zoltán Greff, Krisztina Futosi, Tamás Németh, Laura Simon-Szabó, Krisztina Kerekes, Csaba Szántai-Kis, Diána Brauswetter, Márton Kokas, Gábor Borbély, Anna Erdei, Attila Mócsai, György Kéri, Tibor Vántus, Ramani Ramchandran. Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro. PLOS ONE 2015; 10(4): e0124234 doi: 10.1371/journal.pone.0124234
|
| 115 |
Anne Close. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Future Medicinal Chemistry 2016; 8(4): 443 doi: 10.4155/fmc.16.6
|
| 116 |
Behzad Jafari, Maryam Hamzeh-Mivehroud, Michael B. Morris, Siavoush Dastmalchi. Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge. Cytokine & Growth Factor Reviews 2019; 46: 54 doi: 10.1016/j.cytogfr.2019.03.002
|
| 117 |
Bradley D. Menz, Jacinta L. Johnson, Davina F. Gillard, William Chong, Michael B. Ward. The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. Journal of Pharmacy Practice 2021; 34(3): 386 doi: 10.1177/0897190019872937
|
| 118 |
Wagdy M. Eldehna, Sara T. Al-Rashood, Tarfah Al-Warhi, Razan O. Eskandrani, Amal Alharbi, Ahmed M. El Kerdawy. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry 2021; 36(1): 271 doi: 10.1080/14756366.2020.1862101
|
| 119 |
Tasuku Matsuoka, Masakazu Yashiro. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World Journal of Gastrointestinal Oncology 2021; 13(5): 366-390 doi: 10.4251/wjgo.v13.i5.366
|
| 120 |
Sangeetha Reddy, Michael Raffin, Virginia Kaklamani. Targeting Angiogenesis in Metastatic Breast Cancer. The Oncologist 2012; 17(8): 1014 doi: 10.1634/theoncologist.2012-0043
|
| 121 |
Myron Wilde, Danielle Arzur, Blandine Baratte, Dorian Lefebvre, Thomas Robert, Thierry Roisnel, Catherine Le Jossic-Corcos, Stéphane Bach, Laurent Corcos, William Erb. Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation. New Journal of Chemistry 2020; 44(45): 19723 doi: 10.1039/D0NJ05334A
|
| 122 |
Suchandra Roy Acharyya, Plaboni Sen, Thirukumaran Kandasamy, Siddhartha Sankar Ghosh. Dual therapeutic approach to modulate Glycogen Synthase kinase −3 beta (GSK-3Β) and inhibitor of nuclear factor kappa kinase-beta (IKK-β) receptors by in silico designing of inhibitors. Journal of Molecular Graphics and Modelling 2022; 115: 108225 doi: 10.1016/j.jmgm.2022.108225
|
| 123 |
Thaís Meira Menezes, Caio Assis, Alcides Jairon Lacerda Cintra, Roberto Carlos Silva dos Santos, Wilka Karla Martins do Vale, Regildo Max Gomes Martins, Ranilson de Souza Bezerra, Gustavo de Miranda Seabra, Chenglong Li, Jorge Luiz Neves. Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies. ACS Chemical Neuroscience 2021; 12(24): 4500 doi: 10.1021/acschemneuro.1c00521
|
| 124 |
Zofia F. Bielecka, Agata Malinowska, Klaudia K. Brodaczewska, Aleksandra Klemba, Claudine Kieda, Paweł Krasowski, Elżbieta Grzesiuk, Jan Piwowarski, Anna M. Czarnecka, Cezary Szczylik. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell & Bioscience 2017; 7(1) doi: 10.1186/s13578-017-0197-8
|
| 125 |
Antonio Fernando Leis-Filho, Patrícia de Faria Lainetti, Priscila Emiko Kobayashi, Carlos Eduardo Fonseca-Alves, Renée Laufer-Amorim. Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro. Pharmaceutics 2021; 13(6): 897 doi: 10.3390/pharmaceutics13060897
|
| 126 |
I. Duran, J. Lambea, P. Maroto, J. L. González-Larriba, Luis Flores, S. Granados-Principal, M. Graupera, B. Sáez, A. Vivancos, O. Casanovas. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Targeted Oncology 2017; 12(1): 19 doi: 10.1007/s11523-016-0463-4
|
| 127 |
Ching-Liang Chu, Yi-Pang Lee, Cheng-Yoong Pang, Huei-Ru Lin, Chang-Shan Chen, Ren-In You. Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism. International Immunopharmacology 2020; 82: 106357 doi: 10.1016/j.intimp.2020.106357
|
| 128 |
Amal A.M. Eissa, Kholoud F.M. Aljamal, Hany S. Ibrahim, Heba Abdelrasheed Allam. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity. Bioorganic Chemistry 2021; 116: 105318 doi: 10.1016/j.bioorg.2021.105318
|
| 129 |
E. A. Shatokhina, A. G. Turkina, L. S. Kruglova. Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors. Russian journal of hematology and transfusiology 2020; 65(2): 154 doi: 10.35754/0234-5730-2020-65-2-154-173
|
| 130 |
Abdallah Alzoubi, Hassan Shirazi, Ahmad Alrawashdeh, Arwa M. AL-Dekah, Nadia Ibraheem, Khalid A. Kheirallah. The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature. Pharmaceutics 2024; 16(2): 167 doi: 10.3390/pharmaceutics16020167
|
| 131 |
Priyanka Gupta, Keehn Strange, Rahul Telange, Ailan Guo, Heather Hatch, Amin Sobh, Jonathan Elie, Angela M. Carter, John Totenhagen, Chunfeng Tan, Yogesh A. Sonawane, Jiri Neuzil, Amarnath Natarajan, Ashley J. Ovens, Jonathan S. Oakhill, Thorsten Wiederhold, Karel Pacak, Hans K. Ghayee, Laurent Meijer, Sushanth Reddy, James A. Bibb. Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer. Cell Reports 2022; 40(7): 111218 doi: 10.1016/j.celrep.2022.111218
|
| 132 |
Heba T. Abdel‐Mohsen, Eman A. Abd El‐Meguid, Ahmed M. El Kerdawy, Abeer E. E. Mahmoud, Mamdouh M. Ali. Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Archiv der Pharmazie 2020; 353(4) doi: 10.1002/ardp.201900340
|
| 133 |
Marwa A. Fouad, Alaa A. Osman, Noha M. Abdelhamid, Mai W. Rashad, Ashrakat Y. Nabawy, Ahmed M. El Kerdawy. Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-024-01130-5
|
| 134 |
Kiran Mahajan, Nupam P. Mahajan. ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation. Cancer Letters 2013; 338(2): 185 doi: 10.1016/j.canlet.2013.04.004
|
| 135 |
Jaymin J. Kathiriya, Ravi Ramesh Pathak, Alexandr Bezginov, Bin Xue, Vladimir N. Uversky, Elisabeth R.M. Tillier, Vrushank Davé. Structural pliability adjacent to the kinase domain highlights contribution of FAK1 IDRs to cytoskeletal remodeling. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2017; 1865(1): 43 doi: 10.1016/j.bbapap.2016.10.002
|
| 136 |
Paulina Stachyra‑Strawa, Marzanna Ciesielka, Michał Janiszewski, Ludmiła Grzybowska‑Szatkowska. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncology Reports 2021; 46(2) doi: 10.3892/or.2021.8109
|
| 137 |
Jean-Jacques Helesbeux, Laura Carro, Florence O. McCarthy, Vânia M. Moreira, Francesca Giuntini, Niamh O’Boyle, Susan E. Matthews, Gülşah Bayraktar, Samuel Bertrand, Christophe Rochais, Pascal Marchand. 29th Annual GP2A Medicinal Chemistry Conference. Pharmaceuticals 2021; 14(12): 1278 doi: 10.3390/ph14121278
|
| 138 |
Yael Aschner, Gregory P. Downey. The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not. American Journal of Respiratory Cell and Molecular Biology 2018; 59(5): 535 doi: 10.1165/rcmb.2018-0049TR
|
| 139 |
Refaah Mousa Al‐Jassas, Mohammad Shahidul Islam, Abdullah Mohammed Al‐Majid, Mohamed S. Nafie, Matti Haukka, A.F.M. Motiur Rahman, Abdul Majeed Abdullah Alayyaf, Assem Barakat. Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities. Archiv der Pharmazie 2023; 356(8) doi: 10.1002/ardp.202300185
|
| 140 |
Aleksandra Sochacka-Ćwikła, Marcin Mączyński, Andrzej Regiec. FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review. Cancers 2021; 14(1): 87 doi: 10.3390/cancers14010087
|
| 141 |
Chayanon Ngambenjawong, Heather H. Gustafson, Suzie H. Pun. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Advanced Drug Delivery Reviews 2017; 114: 206 doi: 10.1016/j.addr.2017.04.010
|
| 142 |
|
| 143 |
H. M. Kuznietsova. Effect of dihydropyrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine. The Ukrainian Biochemical Journal 2013; 85(3): 74 doi: 10.15407/ubj85.03.074
|
| 144 |
Nurmaya Effendi, Kenji Mishiro, Takeshi Takarada, Daisuke Yamada, Ryuichi Nishii, Kazuhiro Shiba, Seigo Kinuya, Akira Odani, Kazuma Ogawa. Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging. Bioorganic & Medicinal Chemistry 2019; 27(2): 383 doi: 10.1016/j.bmc.2018.12.016
|
| 145 |
T. V. Koshlan, K. G. Kulikov. Analysis to determine the effect of mutations on binding to small chemical molecules. Journal of Bioinformatics and Computational Biology 2022; 20(02) doi: 10.1142/S0219720022400030
|
| 146 |
Wagdy M. Eldehna, Ghada H Al-Ansary, Tarfah Al-Warhi, Maiy Y Jaballah, Mahmoud Elaasser, Mahmoud Rashed. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents. Bioorganic Chemistry 2024; 143: 107037 doi: 10.1016/j.bioorg.2023.107037
|
| 147 |
Godefridus J Peters, Richard J Honeywell. Drug transport and metabolism of novel anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 2015; 11(5): 661 doi: 10.1517/17425255.2015.1041255
|
| 148 |
Kalyani Asgaonkar, Sushruti Tanksali, Kshitija Abhang, Ashwini Sagar. Development of optimized pyrimido-thiazole scaffold derivatives as anticancer and multitargeting tyrosine kinase inhibitors using computational studies. Journal of the Indian Chemical Society 2023; 100(1): 100803 doi: 10.1016/j.jics.2022.100803
|
| 149 |
Pedro A. Ruiz-Castro, Duncan Shaw, Gabor Jarai. Discoidin Domain Receptors in Health and Disease. 2016; : 217 doi: 10.1007/978-1-4939-6383-6_12
|
| 150 |
Diego Carvalho, Margot Paulino, Fabio Polticelli, Florencia Arredondo, Robert J. Williams, Juan A. Abin-Carriquiry. Structural evidence of quercetin multi-target bioactivity: A reverse virtual screening strategy. European Journal of Pharmaceutical Sciences 2017; 106: 393 doi: 10.1016/j.ejps.2017.06.028
|
| 151 |
Saveria Pastore, Daniela Lulli, Giampiero Girolomoni. Replica to K. Takeda et al. Commentary to Pastore et al. (2014): Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Archives of Toxicology 2014; 88(12): 2321 doi: 10.1007/s00204-014-1399-z
|
| 152 |
Hao-tian Zhang, Lu Wang, Jing Ai, Yi Chen, Chang-xi He, Yin-chun Ji, Min Huang, Jing-yu Yang, Ao Zhang, Jian Ding, Mei-yu Geng. SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET–Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics 2014; 350(1): 36 doi: 10.1124/jpet.114.214817
|
| 153 |
Ting Guo, Shutao Ma. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. ChemMedChem 2021; 16(4): 600 doi: 10.1002/cmdc.202000658
|
| 154 |
GJ Peters. Precision medicine in cancer: beyond wishful thinking?. Expert Review of Precision Medicine and Drug Development 2016; 1(1): 1 doi: 10.1080/23808993.2016.1140555
|
| 155 |
Daniel Dahis, Dana Meron Azagury, Fadi Obeid, Michelle Z. Dion, Alexander M. Cryer, Mariana Alonso Riquelme, Pere Dosta, Ariel William Abraham, Moshe Gavish, Natalie Artzi, Yosi Shamay, Haim Azhari. Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles. Advanced NanoBiomed Research 2023; 3(2) doi: 10.1002/anbr.202200142
|
| 156 |
Rajesh Kumar, Monika Sharma, Sarita Sharma, Rajesh K. Singh. Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I. 2022; : 105 doi: 10.2174/9789815040074122010006
|
| 157 |
Wagdy M. Eldehna, Raed M. Maklad, Hadia Almahli, Tarfah Al-Warhi, Eslam B. Elkaeed, Mohammed A. S. Abourehab, Hatem A. Abdel-Aziz, Ahmed M. El Kerdawy. Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights. Journal of Enzyme Inhibition and Medicinal Chemistry 2022; 37(1): 1227 doi: 10.1080/14756366.2022.2062337
|
| 158 |
Shlomit Tamir, Shlomo Gavrielli, Chen Abitbol, Noam Tau, Ahuva Grubstein, Victoria Neiman, Lilach Yosef, Eli Atar, Alona Zer. Association between multitarget tyrosine kinase inhibitors and changes in CT appearance of submucosal fat in the gastrointestinal tract. Tumori Journal 2021; 107(5): 432 doi: 10.1177/0300891621995893
|
| 159 |
Heba T. Abdel-Mohsen, Marwa A. Ibrahim, Amira M. Nageeb, Ahmed M. El Kerdawy. Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-024-01135-0
|
| 160 |
Yara A. Zaky, Mai W. Rashad, Marwa A. Zaater, Ahmed M. El Kerdawy. Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal–regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-023-01081-3
|
| 161 |
Ranjana K. Kanchan, Jawed A. Siddiqui, Sidharth Mahapatra, Surinder K. Batra, Mohd W. Nasser. microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy. Molecular Cancer 2020; 19(1) doi: 10.1186/s12943-020-1140-x
|
| 162 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 123 doi: 10.1016/B978-0-12-809400-6.00006-8
|
| 163 |
Pooja Gupta, Tavneet Kaur Makkar, Lavisha Goel, Monika Pahuja. Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. Immunologic Research 2022; 70(6): 725 doi: 10.1007/s12026-022-09307-7
|